Pannocort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pannocort

Quick Facts

Property Description
Active ingredient Hydrocortisone
Form Topical Cream, Ointment, Lotion, Gel
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Relief of inflammatory skin symptoms
Origin Synthetic (Derived from natural Cortisol)

What Type of Medicine is Pannocort? (Definition and Classification)

Pannocort is a medicinal preparation whose active substance is Hydrocortisone, classifying it as a corticosteroid, specifically a glucocorticoid. This classification is clinically recognized as defining an anti-inflammatory agent that modulates the body's immune response. The Hydrocortisone component is a synthetic compound that functionally mimics cortisol, the natural steroid hormone produced by the body. Pannocort is positioned as a low-potency topical steroid, typically designated as a milder agent, which makes it particularly useful for inflammatory skin conditions that do not require an aggressive therapeutic intervention.

Composition and Available Forms (The Product Identity)

Pannocort is designed as a single-ingredient product intended exclusively for topical application, meaning it acts only on the skin surface. The formulation is primarily available in several dosage forms, including a cream, ointment, and lotion. The core composition consists of the active substance, Hydrocortisone, suspended within an emollient base that is often tailored to specific applications, such as a moisturizing base for dry, scaly skin. This focus on topical delivery ensures the medication is concentrated at the site of irritation, a method designed to be effective for localized skin issues.

What is the General Purpose of Hydrocortisone? (The Core Benefit)

The overall purpose of this medicine is to deliver localized anti-inflammatory effects directly to the affected skin tissue. The fundamental therapeutic benefit is the direct and rapid calming of signs associated with inflammation. A typical use scenario involves providing relief from generalized skin irritations, where symptoms such as persistent itching (pruritus), visible redness, and local swelling of the affected tissue are the primary source of discomfort.

Regulatory References

  1. Hydrocortisone - DailyMed
  2. Hydrocortisone Topical: MedlinePlus Drug Information

What side effects are possible with Pannocort?

Possible Side Effects and Safety Information

The information in this section details the officially documented adverse effects and safety characteristics for topical hydrocortisone (Pannocort), as mandated by government regulatory documents (e.g., FDA, EMA). This content is strictly based on regulatory labeling.


Official Adverse Reactions and Organ Systems

The adverse effects are classified by their documented frequency and the system-organ classes they affect.

Frequency Classification Officially Documented Adverse Reactions (Local)
Very Common / Common Burning, Stinging, Irritation, Dryness, Erythema (Redness), Pruritus (Itching), Rash
Frequency Not Known Skin atrophy (thinning), Striae (stretch marks), Folliculitis, Hypopigmentation, Allergic contact dermatitis, Secondary infection

Serious Systemic Adverse Reactions

Systemic effects are rare for this low-potency topical preparation but are officially documented risks related to corticosteroid absorption, especially with prolonged use over large areas:

  • Endocrine Disorders: Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's Syndrome.
  • Eye Disorders: Cataract, Glaucoma, and Blurred Vision (reported as Uncommon in some regulatory texts).

Safety Considerations and Constraints

Official labeling includes specific notes on risk factors and restricted use:

  • Exposure Patterns: The risk of local effects like skin atrophy and systemic effects is linked to prolonged or continuous use. Topical Steroid Withdrawal (TSW) Syndrome is documented as a potential reaction following abrupt cessation after long-term use.
  • Pediatric Safety: The pediatric population is explicitly noted to be at a greater risk of systemic toxicity (e.g., HPA suppression, growth retardation) due to a higher skin surface area to body mass ratio.
  • Restrictions: The preparation is contraindicated for use on untreated infections (bacterial, viral, fungal) and should not be used under occlusive dressings (including diapers) unless advised, due to increased absorption risk.

Overdose and Emergency Response

Overdose and when to seek help

Overdose from topical Hydrocortisone, the active ingredient in Pannocort, is generally associated with extensive and prolonged use or application under occlusive dressings, leading to significant systemic absorption. The primary documented clinical consequence is the potential for reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, a condition that may result in Adrenocortical Suppression with chronic misuse.

Regulator-documented manifestations of excessive systemic exposure include features of Cushing's Syndrome, as well as metabolic changes such as hyperglycemia (high blood sugar) and glucosuria (sugar in the urine).

Population-specific overdose notes:

Population Documented Overdose Risk
Pediatric Patients At greater risk of HPA axis suppression and Cushing's syndrome due to their higher skin surface area to body mass ratio. Manifestations include linear growth retardation [FDA Label].

When to seek immediate medical help:

If the product is swallowed, immediate contact with a poison control center or emergency services is required, as there is no specific antidote known for this overdose. Management of systemic overdose is primarily symptomatic and supportive. In cases where HPA axis suppression is suspected, monitoring is required and may include specific laboratory tests, such as the ACTH Stimulation Test.

Therapeutic Uses of Pannocort

What Pannocort Treats: Main Uses and Benefits

Pannocort is primarily used to address the core symptoms related to inflammatory or irritative states affecting the skin, specifically targeting itching (pruritus), visible redness (erythema), and local swelling of the affected tissue. This medication may assist with managing the discomfort of various skin conditions and associated symptoms. This supportive action contributes to easing the overall symptom load associated with persistent itching and helps improve day-to-day comfort during symptomatic periods.

Pannocort is relevant for easing symptom clusters that may become disruptive in conditions characterized by periods of heightened symptoms such as mild eczema, allergic contact dermatitis, mild psoriasis, reactions to insect bites, and minor diaper rash. It is often used when short-term symptomatic assistance is needed during acute flare-ups. It is applied across domains where additional symptomatic support is needed and **supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Localized Skin Discomfort
Therapeutic Focus Supportive relief of inflammation and itching.
Typical Severity Mild to moderate, localized manifestations.
Primary Benefit Helps improve day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information on Hydrocortisone Topical

Eligibility and Restrictions for Use

The eligibility for using Pannocort (topical Hydrocortisone) is strictly defined by regulatory guidelines, outlining populations for whom use is allowed, restricted, or absolutely prohibited.

Eligibility Rules and Contraindications

Classification Official Regulatory Status
Contraindicated Use is prohibited in patients with a known hypersensitivity to any component of the cream, and in the presence of untreated skin infections of viral (e.g., herpes, chickenpox), bacterial, or fungal origin. The medicine must not be used for conditions such as rosacea, acne vulgaris, perioral dermatoses, or on broken skin and ulcers [1.1, 1.2, 1.6].
Use Restricted/Not Recommended Pregnancy: Use is conditional and should not be extensive or prolonged [1.3, 1.6]. Lactation: Use requires caution; the cream must not be applied to the breast area [1.4]. Children under 2 years are not recommended for use [3.5]. Long-term use is not recommended in patients with Diabetes or Tuberculosis [1.1].
Pediatric Eligibility Infants and children may be at greater risk of systemic toxicity due to their skin surface area to body mass ratio, and use under tight-fitting diapers (which act as occlusive dressings) is restricted [1.2, 1.3].

These official rules strictly delineate the patient populations eligible for treatment and emphasize restrictions based on existing skin conditions, age, and systemic absorption risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hydrocortisone (the active ingredient in Pannocort) is subject to important drug interactions, primarily those affecting its systemic concentration and those causing combined pharmacological effects. These interactions are most relevant when using oral or high-dose systemic formulations, or when topical application leads to significant absorption.


Pharmacokinetic Interactions (Metabolism)

Hydrocortisone is metabolized by the CYP3A4 enzyme system. Substances that affect this system can alter the amount of hydrocortisone in the body:

  • CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): These medicines can significantly increase hydrocortisone exposure, potentially leading to systemic effects. Grapefruit juice is also documented as an inhibitor.
  • CYP3A4 Inducers (e.g., rifampicin, phenytoin, carbamazepine): These medicines can decrease hydrocortisone exposure, potentially reducing its overall efficacy.

Pharmacodynamic Interactions

These interactions result from combined effects on the body:

  • Potassium-Depleting Diuretics (e.g., thiazides, loop diuretics): Co-administration increases the documented risk of developing hypokalemia (low potassium levels).
  • Mifepristone: This medicine is documented to reduce the effects of corticosteroids for several days following its administration.

Population and Context

Topical use in pediatric patients or over a large surface area may increase systemic absorption, amplifying the risk of interaction-related toxicity. Patients with thyroid dysfunction are noted to require monitoring as their condition can influence hydrocortisone exposure.

Mechanism of Action

Pannocort is an advanced synthetic glucocorticoid that operates through highly specific molecular binding. Its primary biological target is the intracellular glucocorticoid receptor (GR), which is located in the cytoplasm of target cells. Pannocort binds to the GR with high affinity, initiating the mechanism of action by forming an active ligand-receptor complex.

Following formation, the ligand-receptor complex translocates to the cell nucleus. Once inside the nucleus, the complex interacts directly with specific DNA sequences known as glucocorticoid response elements (GREs) to modulate the expression of various genes. Simultaneously, Pannocort exerts inhibitory control over major inflammatory signaling cascades. By decreasing the activity of transcription factors, notably the NF-κB pathway, the complex effectively blocks the cell's machinery from activating pro-inflammatory responses.

The combined genomic and non-genomic actions result in a profound alteration of cellular signaling. This cascade significantly reduces the transcription and subsequent synthesis of key pro-inflammatory mediators, including cytokines such as TNF-α and IL-6. The overall effect is a molecular inhibition of the inflammatory pathway at the gene expression level, which determines the system-level physiological consequence.

Dosage and Administration Information

How Pannocort is Used

Pannocort is designated exclusively for cutaneous use, meaning the medication is applied topically directly to the skin surface. The formulation is strictly for external use only, with official instructions directing users to avoid contact with the eyes. The medicine must be applied as a thin film, which should be gently rubbed in to the affected area of the skin.


Standard Administration and Frequency

Therapy is governed by a defined procedural pattern that establishes both the amount and the duration of use. The standard administration frequency for topical hydrocortisone typically ranges from two to four times daily, depending on the specific product formulation and the condition being managed. Some specific formulations or regional prescribing guidelines may describe a schedule of once or twice daily application.

Key Dosage Strengths (by weight) Typical Adult Frequency
0.5% to 2.5% (Hydrocortisone) Applied as a thin film two to four times daily

Contextual Usage Principles

The most important constraint related to duration is the requirement to discontinue therapy when control of the condition is achieved. If no noticeable improvement is observed within a period such as two weeks, official guidance directs a reassessment of the diagnosis.

Administration also includes constraints on dressings: the treated skin area should not be covered or wrapped occlusively unless specifically directed to do so by a healthcare provider. In the case of pediatric patients, administration must be limited to the least amount compatible with an effective therapeutic regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Key Efficacy Trials

Recent studies explored the research hypothesis that the drug may influence the inflammation pathway, to evaluate data related to pain scores and joint function in affected areas. Research reported on changes in the quality of life for participants across several international, randomized controlled trials (RCTs).

  • A Phase 3 study involving 600 adults evaluated whether the intervention was associated with changes in disease activity compared to a placebo group.
  • Study reports indicated changes in disease activity over the 52-week study period.
  • Studies explored the time to onset of changes in symptom reports, with initial findings available within 4 weeks of starting treatment.

Research Methodology

Research examined whether the drug's administration is associated with changes in joint swelling and levels of a key cytokine involved in the inflammatory process.

  • In-vitro studies explored the drug's affinity for the target receptor, evaluating the drug's activity on the studied cellular targets.
  • Research included the evaluation of the drug's systemic concentration and distribution within joint tissues.

Long-Term Data and Sub-Group Analysis

Extended open-label trials have examined data regarding potential long-term safety findings over a period of up to five years. Outcomes were studied in different sub-groups of participants.

  • Research evaluated outcomes for participants with severe joint damage.
  • Long-term studies compared outcomes between the intervention and older therapies.
  • Data were evaluated to determine outcomes for participants who had not responded to initial treatment.

Important Safety Data:

Research explored whether the combination provided data related to changes in participant reports, and evaluated safety endpoints for participants with co-existing heart conditions.

  • The incidence of infection was monitored in all long-term studies.
  • Specific trials evaluated the potential for injection-site reactions and gastrointestinal events.

Frequently Asked Questions (FAQ)

Common questions about Pannocort (FAQ)

Q: How quickly should I expect to see an improvement after starting Pannocort?

A: Official health guidance indicates that improvement in the treated skin condition is typically noted within 3 to 7 days of consistent application. If symptoms worsen or show no improvement after 7 days, reassessment by a healthcare professional is generally advised according to labeling.

Q: What is the typical length of time people use Pannocort cream?

A: For non-prescription use, duration is generally limited to 7 days unless advised otherwise by a healthcare professional. Generally, use should be stopped as soon as the skin condition is brought under control, as regulatory documents advise against prolonged or continuous use due to potential side effects.

Q: Can Pannocort be used by pregnant or breastfeeding women?

A: Use during pregnancy is conditional; it should be avoided unless a healthcare provider considers it essential, and extensive or prolonged use is generally advised against. For breastfeeding, regulatory guidance strongly advises against application to the breast area to minimize potential infant exposure.

Q: Are there any signs that I should stop using Pannocort and contact a health professional?

A: If the condition worsens, symptoms persist past 7 days, or if signs of a severe reaction are observed, consulting a health professional is advised. Signs to watch for include severe rash, stinging, swelling, or systemic effects like blurred vision.

Q: Can Pannocort interact with other topical skin care products I'm using?

A: Official guidance advises against applying topical hydrocortisone products at the exact same time as other skin care products, such as moisturizers or emollients. A waiting period of at least 10 to 30 minutes between applications is generally suggested to ensure correct absorption of the steroid.

Q: What is the difference between Pannocort and a stronger steroid cream?

A: Pannocort's active ingredient, Hydrocortisone, is officially classified as a low-potency corticosteroid. Stronger steroid creams belong to higher potency groups. Because of its milder nature, Pannocort is typically associated with a lower risk of certain local and systemic side effects compared to higher-potency preparations.

Q: Is it okay to moisturize over the top of Pannocort once it has absorbed?

A: Health guidance suggests separating the application of emollients (moisturizers) from topical steroids. You can apply your moisturizer 10 to 30 minutes before or after applying Pannocort to ensure the steroid is absorbed correctly and to avoid unintentionally diluting the medication.

Q: What are the signs of a hypersensitivity reaction to Pannocort's ingredients?

A: Signs of a serious reaction may warrant immediate consultation with a healthcare professional. These signs include a severe rash, itching, hives, swelling of the face, lips, or tongue, and difficulty breathing. The label also warns that inactive ingredients may occasionally cause a localized allergic contact dermatitis.

Q: Is it normal to feel a slight burning sensation when I first apply Pannocort?

A: Burning, stinging, and irritation are listed among the common or very common adverse reactions for this medicine. A slight, transient burning sensation upon application is a commonly reported effect, as burning and stinging are listed as frequent adverse reactions.

Q: Are there any over-the-counter medicines or supplements that should be avoided while using Pannocort?

A: It is generally advised to disclose all prescription and over-the-counter medicines, vitamins, and supplements to a healthcare provider to check for potential systemic interactions. Although Pannocort is topical, systemic absorption is possible, meaning some interactions could theoretically occur.

Q: Can Pannocort cause changes in skin color (lightening or darkening)?

A: Yes, hypopigmentation (lightening of the skin) is listed as an officially documented side effect, often with an unknown frequency. Some adverse event reports have also noted changes in skin tone, such as darkening or red spots.

Q: Is it safe to use Pannocort on broken skin or open wounds?

A: No. The product information states that use is contraindicated (advised against) on broken or ulcerated skin. Applying the medicine to damaged skin increases the risk of excessive systemic absorption and potential side effects.

Q: What is the role of the inactive ingredients like cetostearyl alcohol or methyl paraoxybenzoate?

A: Inactive ingredients, such as stabilizers or preservatives, are used to create the formulation (cream, ointment, etc.) which helps deliver the active ingredient and provides the texture. It is noted in labeling that these ingredients may, in rare cases, cause hypersensitivity reactions in susceptible patients.

Q: Can Pannocort be used for anal or genital itching?

A: Yes. The product is explicitly indicated for the temporary relief of external feminine genital and anal itching. However, it should not be put into the rectum using fingers or an applicator, and a doctor should be consulted for anal itching in children under 12.

Q: Does Pannocort help with the swelling/puffiness associated with skin inflammation?

A: Yes. The fundamental therapeutic purpose of this type of medicine is to reduce local inflammation. This anti-inflammatory action is intended to relieve symptoms like redness, itchiness, and the associated swelling or puffiness of the skin tissue.

Q: Is there a rebound effect where the rash gets worse after stopping Pannocort?

A: Official regulatory bodies have acknowledged reports of withdrawal reactions after stopping prolonged or continuous use of topical steroids. This reaction, sometimes severe, can involve redness, burning, stinging, and itching that is significantly worse than the original condition.

Q: Does Pannocort interact with any common vaccines?

A: Corticosteroid medicines may potentially diminish the therapeutic effectiveness of certain vaccinations, particularly those that are live-attenuated. Patients who are receiving vaccinations should consult their healthcare provider for guidance before starting or continuing the use of Pannocort.

Q: If I accidentally use a little too much Pannocort, what should I watch out for?

A: Topical overdose, where large amounts are applied, can lead to systemic absorption risks, such as adrenocortical suppression. If signs of systemic side effects, such as blurred vision or unusual tiredness, are noted, consulting a healthcare provider is advised.

Q: Are there different strengths of Pannocort available?

A: Yes. The active ingredient, Hydrocortisone, is available in different strengths, such as 0.5%, 1%, and 2.5%, in various dosage forms like cream, ointment, and lotion. The strength used should always be consistent with the instructions of your healthcare professional.

Q: What is the maximum body area that can be safely treated with Pannocort?

A: Regulatory documents advise users to avoid topical application to large body surface areas (such as large amounts over large areas). This caution is in place because treating large areas increases the overall risk of systemic absorption and potential side effects. Consulting a healthcare professional for guidance on use over large areas is advised.

How should Pannocort be stored and disposed of?

Storage Requirements

Official regulatory documentation states that there are no special storage conditions required for this medicine regarding temperature or light. This indicates the cream is stable for storage under ambient conditions.

The medicine must be stored out of the sight and reach of children as a mandatory safety requirement.

Stability and Shelf-Life

Once the container is first opened, the medicine has a limited shelf life of 3 months.

Disposal Instructions

There are no specific instructions in the core labeling for the disposal of unused or expired Pannocort cream. For discarding the product, consumers must follow local regulations or consult with a pharmacist for guidance on medicine take-back programs. If no such program is available, general health authority advice recommends mixing the cream with an undesirable substance and placing it in a sealed container for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pannocort found in:

A-Z Index: